However, current immunotherapies, including checkpoint inhibitors targeting the PD-1/PD-L1 or CTLA-4 pathways, face substantial challenges in HCC due to the profoundly immunosuppressive metabolic landscape (15). The gene discussed is CTLA4; the disease is hepatocellular carcinoma.